Dear Reader,
Before Bear Stearns collapsed … Lehman Brothers went bankrupt … and Washington Mutual became the largest bank failure in American history …
Our company Weiss Ratings was already warning investors about these risks.
Unfortunately, by the time most Americans realized how serious the problem was, the financial crisis was already upon us and much of the damage was already done.
That’s why we’re speaking out today.
The founder of Weiss Ratings, Martin Weiss, a Wall Street Journal, BusinessWeek and New York Times best-selling author …
Has been running Weiss Ratings as a 100% conflict-free, independent financial rating agency for 55 years.
And during those 55 years, he’s publicly warned investors before six major American crashes.
Right now, he believes another dangerous credit crisis is building beneath the surface.
Banks … insurance companies and annuities … investment funds and retirement portfolios could all feel the effects if it spreads.
However, many Americans don’t realize how exposed their money already is.
Don’t make that mistake.
That’s why he’s laid out five specific steps you can take now to help protect your wealth before this new crisis spreads.
The first step alone could help you identify where your money could be vulnerable. And the remaining steps show you what he believes you should consider doing with your money instead.
Please don’t wait for another Lehman-style headline before you take this seriously.
See Martin’s warning and the five steps he recommends taking now
Sincerely,
Eliza Lasky
Weiss Advocate
Beam Fell on a Trial It Won. Here Is What That Leaves.
On November 10, Beam Therapeutics experienced a share price decline of nearly 7% following the announcement of promising outcomes from its Phase 1/2 BEACON trial of risto-cel for sickle cell disease. The data was not ambiguous. The BEACON study achieved its primary endpoint of freedom from severe vaso-occlusive crises for at least 12 consecutive months. As of the October 20 data cutoff, 39 adults and 10 adolescents had received the one-time cell therapy, with 31 patients completing the required follow-up period. The trial also met all primary safety endpoints and all secondary efficacy endpoints, including freedom from inpatient hospitalization for severe vaso-occlusive crises for at least 12 consecutive months.
Markets don’t need clean data. They need a reason to hold premium through the next event. When Beam reported those results Tuesday morning, the catalyst the options market had been pricing for months was consumed. The stock dropped. That is not a contradiction. That is exactly how event-driven volatility resolves.
The Commercial Overhang the Data Cannot Solve
If approved, risto-cel could become the first base-editing therapy to receive FDA approval. Beam’s BLA submission is expected as early as year-end 2026, a milestone the company says would bring a potentially transformative treatment to patients with sickle cell disease. The science, in other words, is now largely settled. What is not settled is whether a third entrant in a market that has struggled to absorb the first two can build a viable commercial operation.
Casgevy and Lyfgenia, the first two gene therapies approved for sickle cell disease on the same day in December 2023, have faced challenges related to treatment complexity and high costs. Casgevy carries a list price of about $2.2 million, while Lyfgenia is priced around $3.1 million. Despite their curative potential, uptake has been slow. In 2025, 64 people received infusions of Casgevy. Vertex is now showing early traction: it reported $218.5 million in Casgevy revenue through the first nine months of 2026, including $99.2 million in Q3 2026, up roughly 30% sequentially from Q2. But the trajectory took time to establish.
The rollout has hit a surprisingly basic but formidable obstacle: centers cannot collect enough stem cells from the blood to manufacture the product for many patients. Beam’s management has argued that risto-cel’s manufacturing process is more predictable, but that claim will face the same infrastructure reality that slowed its predecessors. Analyst price targets range from $26 to $80, reflecting divergent views on the commercial potential of Beam’s pipeline.
Options Market: The Crush Is the Story
Shares of BEAM opened at $27.02 on Tuesday and closed at $25.15, versus the prior close of $27.02. That gap illustrates the volatility collapse directly. Options buyers who entered before the readout paid for a range that the event consumed in a single session, leaving holders of long gamma with a realized move smaller than the premium paid implied.
One research analyst has rated the stock with a Strong Buy, nine have assigned a Buy, two a Hold, and one a Sell. The average rating is “Moderate Buy” with an average price target of $47.36. At current levels near $24 to $25, that consensus target represents significant upside on paper. The gap between analyst conviction and market behavior is the tension structures should be built around.
That gap between analyst targets and market price is a recurring pattern in rare-disease biotech after a data catalyst is consumed. AstraZeneca’s IgA nephropathy readout showed how options markets price well-telegraphed FDA events and then collapse on resolution.
Beam last reported quarterly results on November 3 for the quarter ended September 30, 2026. The company reported a loss of $1.28 per share. There is no near-term fundamental catalyst to re-inflate premium until the BLA filing itself, which Beam says could arrive before year-end.
Structured Trade Framework
Bull case. For traders expecting the BLA filing to arrive before December 31 and FDA acceptance to follow in early 2027, a defined-risk debit call spread targeting the $28 to $32 range captures upside without requiring a full return of pre-readout premium. Post-crush IV levels reduce entry cost relative to last week.
Bear case. If the commercial ceiling set by Casgevy and Lyfgenia suppresses risto-cel revenue expectations through 2027, the stock faces structural pressure near current levels. A defined-risk put spread below $20 reflects the 52-week low of $20.23 as the first meaningful support. The 52-week high stands at $38.26, set in July 2026, making the current range a midpoint, not a floor.
Neutral case. With the event resolved and the BLA filing not yet confirmed, a short strangle or iron condor centered near $24 collects residual premium while the stock consolidates. This structure fits a scenario where the filing arrives on schedule but the market’s reaction is muted, as markets have already seen the pivotal data.
Risk Analysis and Forward Outlook
Beam plans to present detailed pivotal results at a medical meeting in 2027. That means the next hard catalyst is the BLA submission confirmation. Failure to file before year-end would shift sentiment sharply. The commercial risk is structural: Beam would be third to market with a genetic therapy for sickle cell, meaning it will have to battle with already established therapies in Lyfgenia and Casgevy. On the balance sheet, the company ended 2025 with about $1.25 billion in cash, cash equivalents, and marketable securities, and it has guided to a cash runway into mid-2029.
Action Checklist
- Monitor Beam’s BLA filing confirmation: target is year-end 2026. Any delay resets the catalyst calendar.
- Track Casgevy quarterly revenue from Vertex as a proxy for market capacity. Vertex reported $99.2 million in Casgevy revenue in Q3 2026, roughly a 30% sequential increase. Trajectory matters for risto-cel’s addressable opportunity.
- Watch IV levels post-crush. Elevated realized volatility with collapsed implied volatility creates a defined-risk entry window that closes if the BLA announcement reignites premium.
- Note the ASH Annual Meeting in December 2026, where updated BEACON data will be presented: a secondary event risk that could move the stock before year-end.
- Size defined-risk structures to withstand a continued drift toward the $20 support level. The fundamental case is intact; the timing case is not yet confirmed.
